ArticleHepatology international2024

Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.

Makoto Chuma et al.PubMed ↗Publisher ↗

No numbers read from the abstract.